Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...
Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...
Polen Capital, an investment management company, released its “Polen Global Growth Strategy” fourth-quarter 2024 investor ...
Shares of Novo Nordisk fell on Monday, after the Danish pharmaceutical giant said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop ...
Novo Nordisk (NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP-1 drug, CagriSema. The drug, a mix of cagrilintide and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results